Comparative Pharmacology
Head-to-head clinical analysis: GRIFULVIN V versus TOLAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIFULVIN V versus TOLAK.
GRIFULVIN V vs TOLAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins and disrupts fungal mitotic spindle formation, thereby inhibiting fungal cell division. It also interferes with fungal nucleic acid synthesis.
TOLAK (tazarotene) is a retinoid prodrug that is converted to its active metabolite tazarotenic acid, which binds selectively to retinoic acid receptors (RARs) such as RARβ and RARγ; this modulates gene expression involved in cell proliferation, differentiation, and inflammation.
500 mg orally once daily (non-microsize formulation) or 250 mg twice daily; typical duration is 4-8 weeks for tinea capitis, 2-6 weeks for tinea corporis, 4-6 weeks for tinea pedis.
Adults: 200 mg orally twice daily.
None Documented
None Documented
Terminal half-life: 9–24 hours. Clinical context: Steady-state achieved in 2–5 days; prolonged in hepatic impairment.
The terminal elimination half-life of fluorouracil is approximately 10-20 minutes due to rapid catabolism by dihydropyrimidine dehydrogenase. Clinically, this short half-life necessitates continuous infusion for sustained systemic exposure.
Renal (1% unchanged), fecal (33% as metabolites), biliary (minor). Extensive hepatic metabolism; <1% excreted unchanged in urine.
Tolak (fluorouracil) is primarily eliminated via metabolism; less than 10% is excreted unchanged in urine. Fecal excretion accounts for approximately 10-20% of the administered dose.
Category C
Category C
Antifungal
Antifungal